MUC1 and cancer: Additionally, Tmunity Therapeutics recently registered a phase I trial to test the safety, tolerability, feasibility, and preliminary efficacy of MUC1 targeted CAR-T cells (TnMUC1) in TnMUC1-positive advanced cancers, including NSCLC (NCT04025216).